A dosing cup, syringe and bottle of the drug Xyrem, produced by Jazz Pharmaceuticals.

Source: https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html

Envestnet Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 7.7% during the third quarter.

Source: https://www.etfdailynews.com/2023/04/17/balentine-llc-decreases-stake-in-jazz-pharmaceuticals-plc-nasdaqjazz/

Needham & Company LLC reduced their price target on Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating on the stock in a report on Thursday, November 10th.

Source: https://www.americanbankingnews.com/2023/02/12/amalgamated-bank-purchases-1408-shares-of-jazz-pharmaceuticals-plc-nasdaqjazz.html

Platinum Investment Management Ltd. acquired a new position in Jazz Pharmaceuticals in the first quarter worth about $90,000.

Source: https://www.dailypolitical.com/2023/10/28/jazz-pharmaceuticals-plc-nasdaqjazz-shares-sold-by-yousif-capital-management-llc.html